



Cellular and Pathogenesis Mechanisms in Oral Cancer

Guest Editor:

Dr. Jun-Ichi Tanuma

Division of Oral Pathology,
Department of Tissue
Regeneration and
Reconstruction, Faculty of
Dentistry & Graduate School of
Medical and Dental Sciences,
Niigata University, Niigata 951-
8514, Japan

Deadline for manuscript
submissions:

28 February 2026

Message from the Guest Editor

Oral cancer is a multi-step process in which multiple genetic events occur that alter the normal function of oncogenes and tumor suppressor genes. Despite advances in surgical techniques, radiation therapy, chemotherapy protocols and other treatment modalities, long-term survival rates for oral cancer patients have been unsatisfactory for several decades. Furthermore, although most oral cancers arise from oral epithelial dysplasia, a premalignant lesion, useful markers for its early detection are still lacking.

Therefore, this Special Issue aims to provide a "research update" on understanding the molecular regulation of the various pathways associated with oral cancer, allowing for more accurate diagnosis and prognostic evaluation, thereby paving the way for new approaches to treatment and prevention.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)